Hereditary Cancer Panel denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for hereditary cancer panel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why This Denial Happens

Although hereditary cancer panel testing is a laboratory service rather than a pharmaceutical benefit, some BCBS plans apply a preferred-provider or preferred-laboratory framework that functions similarly to a formulary. A non-formulary denial in this context typically means the lab that performed — or would perform — the test is not on BCBS's preferred or contracted laboratory list, or that the specific panel configuration ordered is not among those the plan has pre-approved. It can also arise from billing under a code the plan has categorized as non-covered.

## Why This Is Appealable

Non-formulary or non-preferred denials are appealable when no in-network or preferred-lab equivalent exists that can provide the same clinical service, or when the treating clinician documents a specific clinical reason why the requested lab or panel is medically necessary. Many BCBS plans have a formal exception process; the appeal essentially serves as that exception request. If the denial is based solely on network status and no adequate alternative exists, that argument is strong at both internal appeal and external review.

## Federal Appeal Framework

• Internal appeal: File within the deadline on the denial notice. Include an exception request if the plan has a defined process; the appeal and exception can be submitted together.
• External review (ACA §2719): After final internal denial, independent external review is available — generally within four months.
• Expedited review: If treatment decisions depend on timely test results, request expedited processing.
• State network adequacy rules: For fully-insured plans, the state insurance commissioner may have jurisdiction over adequacy-of-network complaints that underlie this type of denial.
• ERISA §503: Self-funded plan members have full-and-fair review rights.

## Documentation to Gather

1. Ordering clinician's letter stating why the specific panel or laboratory is medically necessary — including any unique clinical validation, turnaround, or test design factors that are relevant to patient care. 2. Demonstration that no adequate in-network alternative exists — a brief written statement from the clinician or practice that the preferred/in-network labs do not offer a clinically equivalent panel for this patient's indication. 3. BCBS preferred laboratory list and coverage policy — obtained from BCBS or your HR portal — identifying any exception pathway and its criteria. 4. Applicable guideline organization's recommendation for this type of testing (e.g., NCCN), submitted as a labeled exhibit. 5. Test requisition and lab documentation confirming the specific panel ordered and the genes interrogated.

## Criteria-Mapping Structure

BCBS exception criteria for non-formulary laboratory services typically include showing clinical necessity and absence of an adequate alternative. List each exception criterion in a two-column table, with the supporting clinical fact on the right. If the plan's policy allows exceptions when the preferred-lab alternative lacks clinical equivalence, document the specific difference between the preferred lab's offering and the ordered panel. Attach the ordering clinician's signed letter and the test requisition as exhibits.